Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)

OBJECTIVE: Farletuzumab is a humanized monoclonal antibody that binds to folate receptor alpha, over-expressed in epithelial ovarian cancer (EOC) but largely absent in normal tissue. Previously, carboplatin plus pegylated liposomal doxorubicin showed superior progression-free survival and an improve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol
Autors principals: Kim, Kenneth H., Jelovac, Danijela, Armstrong, Deborah K., Schwartz, Benjamin, Weil, Susan C., Schweizer, Charles, Alvarez, Ronald D.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4729193/
https://ncbi.nlm.nih.gov/pubmed/26644263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.11.031
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars